There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Xeris Biopharma Holdings Inc. (XERS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0081, or 0.61%, to $1.3381. The Xeris Biopharma Holdings Inc. has recorded 3,461 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.33 and fluctuated between $1.3400 as its day high and $1.2050 as its day low. The current market capitalization of Xeris Biopharma Holdings Inc. is $170.00M. A total of 0.84 million shares were traded on the day, compared to an average of 783.29K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, XERS has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 20,000 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 1 SELLs from insiders. Insiders purchased 236,228 shares during that period but sold 11,228.
In the most recent transaction, Edick Paul R bought 20,000 shares of XERS for 1.45 per share on Dec 13. After the transaction, the insider now owns 1,528,064 company shares. In a previous transaction on May 12, Edick Paul R bought 100,000 shares at 1.40 per share. XERS shares that insider owns now total 1,508,064.
Among the insiders who sold shares, PRESTRELSKI STEVEN disposed of 11,228 shares on Feb 22 at a per-share price of $2.42. This resulted in the Chief Scientific Officer holding 569,780 shares of XERS after the transaction.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for XERS in the last 3 months, the mean price target is $5.25 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, XERS has a high of $3.17 and a low of $1.14.
As of this writing, XERS has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.15 per share and a lower estimate of -$0.19.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XERS is Buy with a score of 5.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.